CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 03/06/23

2023-03-06 16:20:30 ET Cyclacel Pharmaceuticals press release ( NASDAQ: CYCC ): Q4 GAAP EPS of -$0.60 misses by $0.12 . Report final data from dose escalation stage and RP2D determination from the 065-101 study of oral fadraciclib in patients with advanced solid tumors...

- On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2023 and Report Interim data in 2H 2023 - - Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation - - Expect to Report Initial Data from Oral Plogosertib 140-101 Do...

BERKELEY HEIGHTS, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2022 financial ...

BERKELEY HEIGHTS, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief E...

– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib – – 2/3 Partial Responses in Lymphoma and 11/15 Stable Disease in Advanced Solid Tumors – – Expecting Key Data Readouts for Oral Fadraciclib...

BERKELEY HEIGHTS, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to present at the B...

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2022 Earnings Conference Call November 09, 2022 04:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President & Chief Executive Officer Mark Kirschbaum - Senior Vice President & Chief...

Cyclacel Pharmaceuticals press release ( NASDAQ: CYCC ): Q3 GAAP EPS of -$0.42 beats by $0.14 . Net loss for the three months ended September 30, 2022, was $5.1 million, compared to $5.0 million for the same period in 2021. For further details see: Cy...

- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma - - Two Partial Responses in Lymphoma and 11 Stable Diseases in Advanced Solid Tumors - - Expect to Determi...

BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2022 financial results o...